Methods of making and using racemic and optically pure metabolites of sibutramine, and pharmaceutically acceptable salts, solvates, and clathrates thereof, are disclosed. Pharmaceutical compositions and dosage forms are also disclosed which comprise a dopamine reuptake inhibitor, such as a racemic or optically pure sibutramine metabolite, and optionally an additional pharmacologically active compound.

 
Web www.patentalert.com

< Methods for non-invasive analyte measurement from the conjunctiva

< Fourier transform mass spectrometry of complex biological samples

> Endogenous and non-endogenous versions of human G protein-coupled receptors

> Method and apparatus for quantifying tissue fat content

~ 00226